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Ionising radiation (IR) can induce immunogenic cell death in
tumours, an effect likely to contribute to the success associ-
ated with radiotherapy (RT) for cancer. Recent studies suggest
that radiotherapy can be applied as a powerful adjuvant to
immunotherapy, and can even contribute to converting the
irradiated tumour into an in situ vaccine, resulting in specific
immunity against metastases [1].
Importantly, preclinical models of syngeneic tumours
have reliably predicted clinical success in several distinct tu-
mour settings and with several different immunotherapy/
radiation combinations. As a proof-of-principle trial, we have
translated the preclinical evidence of a successful combina-
tion with Flt3 ligand and RT to a protocol of granulocyte–
monocyte colony-stimulating factor (GM-CSF) and IR, and
demonstrated out-of-field objective responses in 27% of pa-
tients with multiple metastases of solid tumours, defined as
an abscopal effect [2]
In-parallel mechanistic studies in the laboratory were
conducted in the syngeneic mouse models of metastatic
breast cancer. Results showed that radiation was synergistic
with anti-CTLA-4 treatment, a strategy to break immune tol-
erance to the tumor. Multiple mechanisms contributed to
thus synergy, including the RT-induced upregulation of a
chemokine that promoted homing of effector T cells to the
tumor. Intravital microscopy demonstrated that while both
IR and CTLA-4 blockade given as monotherapy enhanced
the motility of activated CD8 T cells infiltrating 4T1 tumours,
IR with anti-CTLA-4 increased the arrest of T cells in contact
with tumour cells, promoting the formation of an immune
synapse between cytotoxic T cells and their targets. The lat-
ter required interaction between NKG2D on CD8+ T cells and
its ligand, retinoic acid early inducible-1 (Rae-1), on the tu-
mour cells, which was up-regulated by IR. Blocking
NKG2D–Rae-1 interactions markedly increased the motility
of anti-CTLA-4 treated T cells within irradiated tumours,
inhibiting their contact with tumour cells and also abrogated
immune-mediated tumour rejection [4].The preclinical success of the combination of anti-CTLA-4
antibody and IR was mirrored by abscopal responses seen in
metastaticmelanoma and non-small-cell lung cancer (NSCLC)
patients irradiated in one lesion during ipilimumab therapy.
These clinical observations strongly suggest that the effects
of IR identified in experimental models are relevant to
patients. IR can stimulate the anti-tumor immune response,
increasing the proportion of patients who respond to check-
point blockade treatment, an hypothesis currently being
tested in clinical trials. The same pattern of abscopal re-
sponses has been observed in preclinical models was also
demonstrated in clinical cases of lymphomas and breast can-
cers treated by combinations of RT and toll-like receptor ago-
nists. Finally, blocking tumour growth factor beta (TGF-beta)
during RT preclinically has demonstrated abscopal effects that
have been confirmed in one patient accrued to a trial of anti-
humanTGFb antibody fresolimumab andRT.While promising,
this evidence remains preliminary and warrants more re-
search to define the optimal combinations of immunotherapy
and RT, to best exploit this novel role of ionising radiation [3].
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